Postmenopausal osteoporosis is the most common bone metabolic disease associated with low bone mineral density (BMD) and osteopathic fragility fractures, which has been associated with significant disability and mortality.[@b1-cajgh-04-239] The majority of women spend one third of their lifetime in the postmenopausal period typically accompanied by an estrogen deficit state.[@b2-cajgh-04-239] The World Health Organization (WHO) defined osteoporosis as a reduction of 2.5 standard deviations in T-scores below the normal mean for young females at the age of peak bone mass.[@b3-cajgh-04-239] A T score between 1 to 2.5 SDs below average indicates osteopenia, which is a pre-osteoporotic state.[@b3-cajgh-04-239] The diagnostic measurement of Z-score indicates the bone density relative to patients' age and sex.[@b4-cajgh-04-239] A Z-score below −2.0 is classified as below the expected range for that age, while above −2.0 is considered to be within the expected range for a given age.[@b4-cajgh-04-239],[@b5-cajgh-04-239] Worldwide, there are nearly 9 million osteoporotic fractures each year, generating a massive burden both to individuals and to health services.[@b6-cajgh-04-239] About 13--18% of women over the age of 50 years have osteoporosis and 37--50% have osteopenia in the USA.[@b7-cajgh-04-239] Unfortunately, no epidemiologic data have been published about the rate of osteoporosis in Mongolia. Anecdotal evidence suggests that rates in Mongolia are similar to those reported in the USA.

Low estradiol levels are a risk factor for osteoporosis and influences the quality of life for older women.[@b8-cajgh-04-239] Estrogen deficiency can lead to excessive bone re-absorption after menopause.[@b9-cajgh-04-239] To the best of our knowledge, there are no published studies on the relationship between serum reproductive hormonal level and BMD in postmenopausal women in Mongolia. Therefore, the purpose of this study is to evaluate the correlation between reproductive hormone levels such as follicle- stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and osteoporosis among postmenopausal women in Mongolia.

Osteoporosis research is inadequate in Mongolia due to the lack of reliable diagnostic instruments and poor research infrastructure. Conducting such research is valuable to gerontology, endocrinology, and gynecology fields in Mongolia. Hence, the secondary purpose of this study is to establish a research database for future research in related fields.

Methods
=======

Participants
------------

Two hundred sixty women with a mean age of 50.1±4.4 years were included in the study. Participants were recruited from four districts from Ulaanbaatar City of Mongolia. All participants signed informed consents prior to study participation. The study was approved by the ethical committee of Health Sciences University of Mongolia.

Participants were interviewed using a questionnaire developed by the investigators, which included demographics, body mass index (BMI), years since menopause, menarche age, menopause age, and health history. The participants were divided into three different groups based on their BMD value: osteoporosis, osteopenia, and normal. The mean age of the osteoporosis (T score: −2.5), osteopenia (T score: −2.5 to −1), and normal (T score: \>−1) group was 54.0±3.9, 51.5±4.3, and 48.5±3.8 years, respectively. The participants were further classified into four menopausal stages: premenopausal, perimenopausal, postmenopausal early and postmenopausal late using the Staging Reproductive Aging in Women (STRAW).[@b10-cajgh-04-239] Exclusion criteria included: history of bone disease, metabolic and/or endocrine disorders including hyperthyroidism, hyperparathyroidism, diabetes mellitus, liver disease, renal disease, and medications known to affect bone metabolism (e.g., corticosteroids, anticonvulsants, and heparin sodium). None of the participants had a history of medications for the treatment of osteoporosis, such as active vitamin D[@b11-cajgh-04-239], bisphosphonates, selective estrogen receptor modulators (SERM), or calcium.

Laboratory measurements
-----------------------

Five milliliters of fasting peripheral blood were drawn, centrifuged and kept frozen in the −20° C freezer until assayed. Serum samples were evaluated for levels of E~2~, FSH, LH levels, calcium, phosphorus, and vitamin D by ELISA (Thermo Fisher Scientific, USA) method.

Bone mineral density measurements
---------------------------------

The bone ultrasound Mini-Omni (Sunlight, Beammed, Israel) was used to assess BMD. The parameter of speed of sound (SOS) m/s is used for the analysis.[@b12-cajgh-04-239] The SOS refers to the division of transmission time of the sound waves by the length of the body part studied. The forearm and tibia bone scans were performed with the patient on the imaging table using the protocols recommended by the manufacturer. Osteoporosis was defined according to the conventional World Health Organization (WHO) definition.[@b3-cajgh-04-239],[@b13-cajgh-04-239]

Data analysis
-------------

The comparisons of scores between groups were performed using t-tests, and correlations were assessed with the Spearman rank order test, with Bonferonni correction. The data were analyzed using Statistical Package Statistical Software version 20.0 (SPSS Inc., Chicago, IL). Significance was set at p\<0.05 and was two-sided.

Results
=======

Participant Characteristics
---------------------------

Two hundred sixty (n=260) participants aged 50.1±4.4 years were enrolled in the study. The average BMI was 27.3±5.2 kg/m^2^ and mean age of menopause was 48.4±3.4 years.

Factors associated with bone density status
-------------------------------------------

The age of menopause (p=0.002), breastfeeding time (p=0.041), and serum vitamin D (p=0.025) were significantly associated with osteoporotic status. However, there were no statistically significant differences of BMI, menarche age, serum calcium, serum phosphorus, and parathyroid hormone levels noted between the three groups. The result of hormone analysis showed serum estradiol levels were lower in the osteoporotic group than in the normal BMD group (normal: 18.3±13.1 pg/ml, osteoporotic: 15.8±10.7 pg/ml). The FSH and LH levels were higher in the osteoporosis group than in the normal BMD group (FSH normal: 54.5±44.1 pg/ml, FSH osteoporosis: 81.3±34.2 pg/ml, LH normal: 53.1±41.2, LH osteoporosis: 75.1±26.1 pg/ml). Clinical and laboratory characteristics of the participants are listed in [Table 1](#t1-cajgh-04-239){ref-type="table"}.

Correlation of reproductive hormones with menopausal status
-----------------------------------------------------------

Serum estradiol levels were not significantly different across menopause stages. The FSH and LH levels were higher in the postmenopausal late stage than in the premenopausal stage ([Table 2](#t2-cajgh-04-239){ref-type="table"}). The study found a weak statistical correlation between FSH and SOS from the ultrasound (r=−0.16, *p*\<0.01). There was a significant negative correlation between SOS and BMI (r=−0.306, *p*\<0.01). The SOS was significantly different in all four groups (*p*\<0.05).

Analysis of bone mineral density
--------------------------------

The average T score was −0.18±0.6 in the normal BMD group, 1.67±0.4 in the osteopenia group, and −3.18±0.6 in the osteoporosis group. The Z score was 0.29±1.2 in normal patients, −1.64±1.3 in the osteopenia group, and −2.17±1.1 in osteoporosis patient group.

T-score and speed of sound progressively decreased with with age ([Figures 1](#f1-cajgh-04-239){ref-type="fig"} and [2](#f2-cajgh-04-239){ref-type="fig"}). The box plots of T and Z scores of the participants stratified by menopausal status are shown in [Figures 3](#f3-cajgh-04-239){ref-type="fig"} and [4](#f4-cajgh-04-239){ref-type="fig"}.

Discussion
==========

The menopausal period is a normal physiological process that is accompanied by various symptoms.[@b8-cajgh-04-239] The researchers identified that the average age of onset of the menopause is 48--52, and it is similar in women across various countries.[@b14-cajgh-04-239] Recently published study demonstrated that the average age of menopause onset among Mongolian women was 49.3±3.1, 48.6±1.7 and 48.2±2.9 years in 2008, 2010, and 2011, respectively.[@b15-cajgh-04-239] Similarly, in our study, the mean age of menopause for our research participants was 48.4±3.4 years.

The current study showed that the rate of osteoporosis was 11.2% and osteopenia was 34.6%, rates that were similar to results of other Asian women from reports of WHO in 2008.[@b16-cajgh-04-239] Osteoporosis incidence was higher in women with advanced stages of menopause. In our study, FSH and LH levels significantly differed across menopause stages in that those who were post-menopausal had higher levels compared to those who were pre- or peri-menopausal. Both hormones, FSH and LH, showed weak negative correlations with BMD level, but not E~2~. The result was significant in FSH level and SOS (r=−0.16; *p*\<0.01), which was similar to previous studies.[@b17-cajgh-04-239],[@b18-cajgh-04-239] This could indicate that low BMD in later stages of menopause is associated with serum FSH rather than E~2~. The weak correlation may be due to our small sample size. Other limitations of the current study include: participants were only selected from city areas and rural areas were not sampled, and the BMD was only tested in forearm and tibia. Ideally, the most common fracture sites, such as hips and spine, should be tested in future studies.

This is one of the first studies in Mongolia to determine the correlation between the hormonal levels and menopausal status. We concluded that women from older age groups had lower levels of serum estradiol, which were associated with loss of BMD. However, there was significant correlation between FSH and BMD in more advanced stages of menopause. Further study is needed to investigate the bone metabolism related studies to establish better epidemiological data sources among Mongolian population. Authors would like to encourage similar studies in Mongolia and Central Asia, consistent with the need of Cental Asian Region for better-developed chronic disease research.[@b19-cajgh-04-239]
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###### 

Demographic and laboratory characteristics of participants

  Characteristics                Osteoporosis N=30   Osteopenia N=90   Normal N=140   p-value
  ------------------------------ ------------------- ----------------- -------------- -----------
  Mean age                       54.0±3.9            51.5±4.3          48.5±3.8       0.433
  BMI (kg/m^2^)                  28.98±4.0           27.97±5.3         26.55±5.2      0.460
  **Age at Menopause (years)**   48.6±3.6            48.2 ±3.5         48.5±3.2       **0.002**
  Age at menarche (years)        14.72±1.8           14.47±1.7         14.98±1.9      0.464
  Number of birth (n)            3.3±1.5             3.2 ±1.5          2.6±1.2        0.167
  Serum calcium (mmol/l)         2.17±0.3            2.18 ±0.2         2.14±0.2       0.077
  Serum phosphorus (mmol/l)      3.63±0.9            3.76 ±1.0         3.55±0.9       0.261
  Serum PTH (pg/ml)              7.91±4.5            7.62 ±4.2         7.61±5.6       0.565
  **Serum VitD (mmol/l)**        13.28±6.1           12.52 ±4.9        12.58±6.1      **0.025**
  **Breastfeeding time (yrs)**   2.06±1.2            2.43±1.6          2.38±1.6       **0.041**

Significant findings are indicated in bold.

###### 

Levels of reproductive hormones (by STRAW) stratified by menopausal status

  Stage of menopause   Premenopausal N=63   Perimenopausal N=77   Postmenopausal early N=79   Postmenopausal late N=41
  -------------------- -------------------- --------------------- --------------------------- --------------------------
  Estradiol (pg/ml)    29.9±3.1             30.7±4.7              34.0±1.7                    26.3±7.7
  FSH (pg/ml)          26.7±4.7             36.9±4.2              64.6±4.9                    61.0±6.3
  LH (pg/ml)           20.5±3.6             34.4±3.5              62.3±4.7                    59.7±6.9
